NCT03330847 2026-03-10To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.AstraZenecaPhase 2 Active not recruiting273 enrolled 22 charts
NCT02617277 2026-03-04Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid TumoursAstraZenecaPhase 1 Completed56 enrolled